Literature DB >> 26609425

The Brain and Propranolol Pharmacokinetics in the Elderly.

Andy R Eugene1, Wayne T Nicholson2.   

Abstract

Propranolol, a non-selective β-blocker, has been found to have a tremendous array of indications. Recent evidence has suggested that propranolol may be effective in patients suffering from post-traumatic stress disorder by suppressing activity in the amygdala and thereby inhibiting emotional memory formation. Dosage requirements have been well established in the pediatric and adult population, however, there has been no definitive geriatric dose recommended in the package inserts made available to the public. The aim of this paper is to use pharmacokinetic simulations in order to establish a pharmacokinetic profile dosage equivalent for the elderly as has been found in young patients. After completing the Monte-Carlo simulations for the elderly and young patients, a single 10mg dose in the elderly has shown comparable pharmacokinetic profiles as found in young patients administered a 40mg single dose.

Entities:  

Keywords:  brain; elderly; pharmacokinetics; propranolol

Year:  2015        PMID: 26609425      PMCID: PMC4655970     

Source DB:  PubMed          Journal:  Brain (Bacau)        ISSN: 2068-0473


  27 in total

1.  Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.

Authors:  M Pine; L Favrot; S Smith; K McDonald; C A Chidsey
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

2.  Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients.

Authors:  Murray B Stein; Carol Kerridge; Joel E Dimsdale; David B Hoyt
Journal:  J Trauma Stress       Date:  2007-12

3.  Comparison of some properties of pronethalol and propranolol. 1965.

Authors:  J W Black; W A Duncan; R G Shanks
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

4.  Nobel lecture in physiology or medicine--1988. Drugs from emasculated hormones: the principle of syntopic antagonism.

Authors:  J Black
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

5.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Authors:  Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen
Journal:  Bone       Date:  2011-08-11       Impact factor: 4.398

6.  Propranolol treatment for hemangioma of infancy: risks and recommendations.

Authors:  Leslie P Lawley; Elaine Siegfried; Jane L Todd
Journal:  Pediatr Dermatol       Date:  2009 Sep-Oct       Impact factor: 1.588

Review 7.  Beta-adrenergic receptor blockers. Adverse effects and drug interactions.

Authors:  W H Frishman
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

8.  The effect of propranolol on posttraumatic stress disorder in burned service members.

Authors:  Laura L McGhee; Christopher V Maani; Thomas H Garza; Peter A Desocio; Kathryn M Gaylord; Ian H Black
Journal:  J Burn Care Res       Date:  2009 Jan-Feb       Impact factor: 1.845

9.  Human amygdala reactivity is diminished by the β-noradrenergic antagonist propranolol.

Authors:  R Hurlemann; H Walter; A K Rehme; J Kukolja; S C Santoro; C Schmidt; K Schnell; F Musshoff; C Keysers; W Maier; K M Kendrick; O A Onur
Journal:  Psychol Med       Date:  2010-01-27       Impact factor: 7.723

10.  A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.

Authors:  Anne B Taegtmeyer; Manuel Haschke; Lydia Tchambaz; Mirabel Buylaert; Martin Tschöpl; Ulrich Beuers; Jürgen Drewe; Stephan Krähenbühl
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

View more
  1 in total

1.  A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.

Authors:  Andy R Eugene; Jolanta Masiak
Journal:  Nord J Psychiatry       Date:  2017-05-09       Impact factor: 2.202

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.